199 related articles for article (PubMed ID: 30365145)
1. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells.
Tomoyasu C; Kikuchi K; Kaneda D; Yagyu S; Miyachi M; Tsuchiya K; Iehara T; Sakai T; Hosoi H
Oncol Rep; 2019 Jan; 41(1):643-649. PubMed ID: 30365145
[TBL] [Abstract][Full Text] [Related]
2. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Haydn T; Metzger E; Schuele R; Fulda S
Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
[TBL] [Abstract][Full Text] [Related]
3. The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells.
Laszig S; Boedicker C; Weiser T; Knapp S; Fulda S
Cancer Lett; 2020 Aug; 486():46-57. PubMed ID: 32445837
[TBL] [Abstract][Full Text] [Related]
4. Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma.
Heinicke U; Kupka J; Fichter I; Fulda S
Oncogene; 2016 Jul; 35(28):3729-41. PubMed ID: 26616861
[TBL] [Abstract][Full Text] [Related]
5. Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways.
Chen YJ; Wang WH; Wu WY; Hsu CC; Wei LR; Wang SF; Hsu YW; Liaw CC; Tsai WC
PLoS One; 2017; 12(8):e0183368. PubMed ID: 28829799
[TBL] [Abstract][Full Text] [Related]
6. Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
Wang J; Cao Z; Wang F; Wang P; An J; Fu X; Liu T; Li Y; Li Y; Zhao Y; Lin H; He B
Eur J Med Chem; 2021 Dec; 225():113799. PubMed ID: 34500130
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
[TBL] [Abstract][Full Text] [Related]
8. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Zhao B; He T
Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
[TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.
Hedrick E; Crose L; Linardic CM; Safe S
Mol Cancer Ther; 2015 Sep; 14(9):2143-53. PubMed ID: 26162688
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
[TBL] [Abstract][Full Text] [Related]
11. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
[TBL] [Abstract][Full Text] [Related]
12. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor OBP‑801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1‑dependent apoptosis.
Chihara Y; Iizumi Y; Horinaka M; Watanabe M; Goi W; Morita M; Nishimoto E; Sowa Y; Yamada T; Takayama K; Sakai T
Int J Oncol; 2020 Mar; 56(3):848-856. PubMed ID: 32124968
[TBL] [Abstract][Full Text] [Related]
14. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
16. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.
Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S
Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.
North BJ; Almeciga-Pinto I; Tamang D; Yang M; Jones SS; Quayle SN
PLoS One; 2017; 12(3):e0173507. PubMed ID: 28264055
[TBL] [Abstract][Full Text] [Related]
19. Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines.
Marampon F; Di Nisio V; Pietrantoni I; Petragnano F; Fasciani I; Scicchitano BM; Ciccarelli C; Gravina GL; Festuccia C; Del Fattore A; Tombolini M; De Felice F; Musio D; Cecconi S; Tini P; Maddalo M; Codenotti S; Fanzani A; Polimeni A; Maggio R; Tombolini V
Cancer Lett; 2019 Oct; 461():90-101. PubMed ID: 31325529
[TBL] [Abstract][Full Text] [Related]
20. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
